Clinical

Dataset Information

0

A single-arm, prospective, Phase II clinical study of surufatinib in combination with tislelizumab in advanced colorectal cancer after third-line treatment failure

ABSTRACT: Interventions: Test group:Surufatinib+tislelizumab Primary outcome(s): Progression-free survival Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 39907 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Transcriptomics Surufatinib increases cholangiocarcinoma cells radiosensitivity by anti-tumor proliferation and inhibition of macrophage M2 polarization
2024-06-30 | GSE269494 | GEO
Clinical Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
| 2353932 | ecrin-mdr-crc
Clinical A single-arm, prospective, exploratory clinical study of surufatinib combined with sintilimab in advanced colorectal cancer
| 79369 | ecrin-mdr-crc
Unknown Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study.
| S-EPMC6889407 | biostudies-literature
Unknown A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line treatment in patients with metastatic gastric cancer.
| S-EPMC10903192 | biostudies-literature
Unknown Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study.
| S-EPMC8848367 | biostudies-literature
Unknown Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.
| S-EPMC9985926 | biostudies-literature
Unknown Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study.
| S-EPMC9300836 | biostudies-literature
Unknown Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial.
| S-EPMC9931771 | biostudies-literature
Unknown Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
| S-EPMC10186513 | biostudies-literature